Ian WaddellFounder

United Kingdom - Wilmslow, England,

A proven leader,with more than 27 years experience in project, line and matrix management in the pharmaceutical and now CRO industry. Broad experience in all stages of modern drug discovery having managed and motivated large discovery based groups in both cardiovascular and oncology disease areas.
Currently leading a highly motivated international team of Drug Discovery scientists at Charles River Laboratories based in Cambridge, Canterbury, Harlow, Beerse and Leiden.
Previously at The CRUK Manchester Institute Drug Discovery Unit I lead the team which signed partnership deals with AstraZeneca, Genentech, HitGen, Ideaya and GSK. In 2014 I was appointed as the deputy drug discovery lead group for the Cancer Research UK’s Lung Cancer Centre of Excellence established to combine expertise in Manchester and University College London.I wad previously the Postgraduate Tutor looking after the PhD programme at The Cancer Research UK Manchester Institute.

I am an occasional consultant for a number of biotech companies including IOmet Pharma Ltd (formerlyTPP Global Development), C4X Discovery Ltd and HITGEN Ltd . Additionally I am on the scientific advisor panel for HitGen LTD and the GRAM advisory panel for the Brain Tumour Charity. I am also a member of both the MRCT’s Centre for Therapeutics Discovery review panel and the Alzheimer's Research UK drug discovery review panel. I have consulted for Anxiety UK re its drug development tracking strategy on a Pro Bono basis.

Specialties: Oncology, Diabetes and Obesity, Translational Science